journal article·2018-08Open access

Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins

Seah Ling Kuan, Stephan Fischer, Susanne Hafner, Tao Wang, Tatiana Syrovets, Weina Liu, Yu Tokura, David Yuen Wah Ng, Andreas Riegger, Christina Förtsch, Daniela Jäger, Thomas F. E. Barth, Thomas Simmet, Holger Barth, Tanja Weil

Advanced Science· Volume 5· Issue 8

Abstract

Abstract A facile chemical approach integrating supramolecular chemistry, site‐selective protein chemistry, and molecular biology is described to engineer synthetic multidomain protein therapeutics that sensitize cancer cells selectively to significantly enhance antitumor efficacy of existing chemotherapeutics. The desired bioactive entities are assembled via supramolecular interactions at the nanoscale into structurally ordered multiprotein complexes comprising a) multiple copies of the chemically modified cyclic peptide hormone somatostatin for selective targeting and internalization into human A549 lung cancer cells expressing SST‐2 receptors and b) a new cysteine mutant of the C3bot1 (C3) enzyme from Clostridium botulinum, a Rho protein inhibitor that affects and influences intracellular Rho‐mediated processes like endothelial cell migration and blood vessel formation. The multidomain protein complex, SST3‐Avi‐C3, retargets C3 enzyme into non‐small cell lung A549 cancer cells and exhibits exceptional tumor inhibition at a concentration ≈100‐fold lower than the clinically approved antibody bevacizumab (Avastin) in vivo. Notably, SST3‐Avi‐C3 increases tumor sensitivity to a conventional chemotherapeutic (doxorubicin) in vivo. These findings show that the integrated approach holds vast promise to expand the current repertoire of multidomain protein complexes and can pave the way to important new developments in the area of targeted and combination cancer therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer therapeutics and mechanisms · Monoclonal and Polyclonal Antibodies Research · Biochemical and Molecular Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Max‐Planck Institute for Polymer Research Ackermannweg 10 55128 Mainz Germany

Institute of Inorganic Chemistry I Ulm University Albert‐Einstein‐Allee 11 89081 Ulm Germany

Institute of Pharmacology and Toxicology University of Ulm Medical Center Albert‐Einstein‐Allee 11 89081 Ulm Germany

Institute of Pharmacology of Natural Products and Clinical Pharmacology Ulm University Helmholtzstraße 20 89081 Ulm Germany

School of Materials Science and Engineering Southwest Jiaotong University 610031 Chengdu P. R. China

Institute of Pathology Ulm University Albert‐Einstein‐Allee 23 89070 Ulm Germany

Funding

Volkswagen Foundation · European Research Council · Horizon 2020 Framework Programme

References (79)

Show source-provided references
1. 10.1016/j.drudis.2012.02.00410.1016/j.drudis.2012.02.004 ↗
2. 10.2217/fmb.15.6810.2217/fmb.15.68 ↗
3. 10.1038/s41598-017-15251-610.1038/s41598-017-15251-6 ↗
4. 10.1016/j.jconrel.2014.03.04510.1016/j.jconrel.2014.03.045 ↗
5. Zhu Y. · FASEB J. · 2017 · 31 · 942.13
6. 10.1038/nmat470710.1038/nmat4707 ↗
7. 10.1200/JCO.2013.51.448910.1200/JCO.2013.51.4489 ↗
8. A study of bevacizumab in combination with chemotherapy for treatment of osteosarcoma https://clinicaltrials.gov/ct2/show/results/NCT00667342(accessed: April2017).
9. 10.1016/j.actbio.2017.09.00910.1016/j.actbio.2017.09.009 ↗
10. 10.1681/ASN.201002016710.1681/ASN.2010020167 ↗
11. 10.1016/j.cllc.2011.12.00110.1016/j.cllc.2011.12.001 ↗
12. 10.1158/0008-5472.CAN-11-170410.1158/0008-5472.CAN-11-1704 ↗
13. 10.1016/j.bbcan.2009.03.00310.1016/j.bbcan.2009.03.003 ↗
14. 10.4161/sgtp.2901910.4161/sgtp.29019 ↗
15. 10.1016/j.ymthe.2004.08.02910.1016/j.ymthe.2004.08.029 ↗
16. 10.1517/17460441.2015.105877510.1517/17460441.2015.1058775 ↗
17. 10.1182/blood-2014-01-49225610.1182/blood-2014-01-492256 ↗
18. 10.1158/1078-0432.CCR-15-162310.1158/1078-0432.CCR-15-1623 ↗
19. 10.1002/9783527682423.ch1810.1002/9783527682423.ch18 ↗
20. 10.1002/pros.2116410.1002/pros.21164 ↗
21. 10.3389/fmicb.2014.0017210.3389/fmicb.2014.00172 ↗
22. 10.1021/bm301531c10.1021/bm301531c ↗
23. 10.1002/jps.2205410.1002/jps.22054 ↗
24. 10.1007/s10295-014-1440-510.1007/s10295-014-1440-5 ↗
25. 10.1021/acs.biomac.5b0153710.1021/acs.biomac.5b01537 ↗
26. 10.1021/ja408412210.1021/ja4084122 ↗
27. 10.1016/j.addr.2007.05.01610.1016/j.addr.2007.05.016 ↗
28. Haugland R. P. · 1995 · 23510.1385/0-89603-308-2:235 ↗
29. 10.1002/anie.20160466110.1002/anie.201604661 ↗
30. 10.1021/nl900902810.1021/nl9009028 ↗
31. 10.1038/s41551-017-007810.1038/s41551-017-0078 ↗
32. 10.1159/00004916310.1159/000049163 ↗
33. 10.1016/0960-0760(92)90184-K10.1016/0960-0760(92)90184-K ↗
34. 10.1371/journal.pone.017828610.1371/journal.pone.0178286 ↗
35. 10.1002/(SICI)1097-0142(19990101)85:1<188::AID-CNCR26>3.0.CO;2-310.1002/(SICI)1097-0142(19990101)85:1<188::AID-CNCR26>3.0.CO;2-3 ↗
36. 10.1054/bjoc.2001.188110.1054/bjoc.2001.1881 ↗
37. 10.2174/15672011179366363310.2174/156720111793663633 ↗
38. 10.1002/cncr.2876010.1002/cncr.28760 ↗
39. 10.3389/fimmu.2015.0033910.3389/fimmu.2015.00339 ↗
40. 10.1006/bbrc.2000.231510.1006/bbrc.2000.2315 ↗
41. 10.1155/2016/601264210.1155/2016/6012642 ↗
42. 10.1007/s00210-006-0113-y10.1007/s00210-006-0113-y ↗
43. 10.2217/14796694.4.4.45710.2217/14796694.4.4.457 ↗
44. 10.1016/j.vaccine.2013.07.07810.1016/j.vaccine.2013.07.078 ↗
45. Lauro S. · Anticancer Res. · 2014 · 34 · 1537
46. 10.1056/NEJMoa06188410.1056/NEJMoa061884 ↗
47. Shanker M. · Lung Cancer: Targets Ther. · 2010 · 1 · 23
48. Yao Z. · J. Nucl. Med. · 1999 · 40 · 479
49. 10.1042/bj089059910.1042/bj0890599 ↗
50. 10.1089/cbr.2010.079710.1089/cbr.2010.0797 ↗
51. 10.1039/C6SC00005C10.1039/C6SC00005C ↗
52. 10.1038/nchembio78610.1038/nchembio786 ↗
53. 10.1002/chem.20140396510.1002/chem.201403965 ↗
54. 10.1021/ja00035a00410.1021/ja00035a004 ↗
55. 10.1158/2159-8290.CD-12-038810.1158/2159-8290.CD-12-0388 ↗
56. 10.1155/2010/15096010.1155/2010/150960 ↗
57. 10.1002/bies.2080510.1002/bies.20805 ↗
58. 10.1002/3527608761.ch210.1002/3527608761.ch2 ↗
59. 10.1021/mp400096z10.1021/mp400096z ↗
60. 10.1002/1097-0215(20001215)88:6<889::AID-IJC8>3.0.CO;2-N10.1002/1097-0215(20001215)88:6<889::AID-IJC8>3.0.CO;2-N ↗
61. 10.1161/01.ATV.0000054198.68894.8810.1161/01.ATV.0000054198.68894.88 ↗
62. 10.1371/journal.pone.008569510.1371/journal.pone.0085695 ↗
63. 10.1002/mabi.20150041710.1002/mabi.201500417 ↗
64. 10.1007/s11095-007-9454-610.1007/s11095-007-9454-6 ↗
65. 10.1002/elps.115017080810.1002/elps.1150170808 ↗
66. Aktories K. · Curr. Top. Microbiol. Immunol. · 2015 · 384 · 53
67. 10.1111/j.1462-5822.2009.01393.x10.1111/j.1462-5822.2009.01393.x ↗
68. 10.1128/IAI.66.4.1364-1369.199810.1128/IAI.66.4.1364-1369.1998 ↗
69. 10.1074/jbc.M40947720010.1074/jbc.M409477200 ↗
70. 10.1124/mol.109.06047510.1124/mol.109.060475 ↗
71. 10.1158/0008-5472.CAN-08-129610.1158/0008-5472.CAN-08-1296 ↗
72. 10.1080/0363904080197429510.1080/03639040801974295 ↗
73. 10.1016/j.yexcr.2014.06.01010.1016/j.yexcr.2014.06.010 ↗
74. 10.1186/1559-0275-8-1610.1186/1559-0275-8-16 ↗
75. 10.1158/0008-5472.CAN-06-138410.1158/0008-5472.CAN-06-1384 ↗
76. 10.1093/annonc/mdv59310.1093/annonc/mdv593 ↗
77. 10.1634/theoncologist.12-1-7910.1634/theoncologist.12-1-79 ↗
78. Doublier S. · Am. Assoc. Cancer Res. · 2008 · 6 · 1607
79. 10.1124/mol.108.04528610.1124/mol.108.045286 ↗